Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this.
Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.
FAT jabs may lower the risk of the UK’s biggest killer, according to a study of almost 400,000 adults with type 2 diabetes. The research, published in JAMA Neurology, examined two types of ...
Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with ...
19h
Irish Star on MSNAlzheimer’s disease and dementia could be prevented with popular new medicine, research findsHaving already been hailed for their ability to aid weight loss and treat diabetes, GLP-1 drugs like Ozempic and Mounjaro ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...
21h
New Scientist on MSNDrugs like Ozempic and Wegovy could significantly cut dementia riskDozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...
Australia is grappling with an alarming health crisis, one that remains dangerously under the radar for millions of ...
Fat jabs and diabetes drugs like Ozempic and Mounjaro could also ‘slash risk of UK’s biggest killer’
FAT jabs may lower the risk of the UK’s biggest killer, according to a study of almost 400,000 adults with type 2 diabetes. The research, published in JAMA Neurology, examined two types of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results